http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 09 Sep 2026 08:32:06 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Quantum+BioPharma+gets+FDA+clearance+for+MS+drug+trial/27039964.html <p>Quantum BioPharma Ltd. (NASDAQ: QNTM) has received FDA clearance to begin a phase 2 clinical trial of Lucid-MS, a drug candidate targeting multiple sclerosis, according to a company statement.</p><p>Lucid-MS is described as a patented drug candidate designed to protect and potentially repair the myelin sheath, the protective coating on nerve fibers that is damaged in MS patients. The company claims the mechanism differs from existing MS treatments, which focus on modulating the immune system rather than addressing myelin directly.</p><p>According to the company, this would be the first time a drug candidate built on this specific mechanism has been tested in http://www.streetinsider.com/Corporate+News/Quantum+BioPharma+gets+FDA+clearance+for+MS+drug+trial/27039964.html Wed, 09 Sep 2026 08:32:06 -0400 QNTM http://www.streetinsider.com/FDA/Quantum+BioPharma+gets+FDA+clearance+for+MS+drug+trial/27039964.html <p>Quantum BioPharma Ltd. (NASDAQ: QNTM) has received FDA clearance to begin a phase 2 clinical trial of Lucid-MS, a drug candidate targeting multiple sclerosis, according to a company statement.</p><p>Lucid-MS is described as a patented drug candidate designed to protect and potentially repair the myelin sheath, the protective coating on nerve fibers that is damaged in MS patients. The company claims the mechanism differs from existing MS treatments, which focus on modulating the immune system rather than addressing myelin directly.</p><p>According to the company, this would be the first time a drug candidate built on this specific mechanism has been tested in http://www.streetinsider.com/FDA/Quantum+BioPharma+gets+FDA+clearance+for+MS+drug+trial/27039964.html Wed, 09 Sep 2026 08:32:06 -0400 QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Ltd.+NASDAQ%3A+QNTM%29+Receives+FDA+Clearance+to+Begin+Trials+for+Historic+MS+Treatment+/27039858.html <p>NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- via <a href="https://www.globenewswire.com/Tracker?data=f_kGscl0invYHTE5kFOCxxtqlOcxxqjY6ko6dLWavavpav2EHwFkCFosSVWa8iO-elLAV4M8UieMMju1OTFbew==" rel="nofollow" target="_blank">BioMedWire</a> — <a href="https://www.globenewswire.com/Tracker?data=MT9UzliMsHrm7UkS9ZbgpfYGxrbsvTw3GKWbf-9MHBxe2qVXvwc347wXbKGfYNB0jIBmsA_SjDebotktqkE2cSVJyOENApLZTMvu75PJ0y2usbEAg0pRWYLI7ngauyG907_gC_Z-oVUBcNd89daFKd8RfRyl7wCpKxKm_H5UUKE=" rel="nofollow" target="_blank">Quantum BioPharma Ltd.</a> (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by <a href="https://www.globenewswire.com/Tracker?data=f_kGscl0invYHTE5kFOCx64-TlyfOtSoU6ovXpJoQ7TMLl12D0lSKR3TkaEnrLxp4Au9-ZzbGUaeBGaX4UnbCA==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a href="https://www.globenewswire.com/Tracker?data=L703BjSxyNo-n6sy9QI_Z06tD6tMHAA09Oqi37ECXW1krKa_8Svd81U4GgPfQl68zR0ClzeCzonRzuSddvui-A7zk0DNC37e754amCGFZmbDOnCrcH_7UnpCSQI19ZCJg9lWCVIGmkzbrCbpvT4ETA==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a href="https://www.globenewswire.com/Tracker?data=H6Wvm6XbXEO_lElsiEHRPDNsp_8MtL6g5TO06CpfFuqAuui3kZhwo0EAf_aKIN_MN_B6qjBdUH5hyg3ag0oONQxSnNjH23BI4OKWYXg99Nw=" rel="nofollow" target="_blank">IBN</a> (<a href="https://www.globenewswire.com/Tracker?data=JAowqG4tafr-_LYyByHfekaQQ9OsqhYfdrdiFju7-UcEvzNMmAGgtTK2u4_3YkSc-7XlnW11-LxC1lxVYIsPYlxZWYJnQg1o0JK706QCkcI2QSpzEpuTgbbXai5R8QEF" rel="nofollow" target="_blank">InvestorBrandNetwork</a><u>)</u>, a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.</p> <p>To view the full publication, “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” please visit: <a href="https://www.globenewswire.com/Tracker?data=TWkN9tWt81iJCypMQTVfTJ-MKBXjKs_P82afVWteLlwtzbzZ1U9pA4hP7-PN8nJTeHlQ5TtDjhpABwUEI_br7YSE2zSw4XpZGGITq15Ox38=" rel="nofollow" target="_blank">https://ibn.fm/b9zkB</a></p> http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Ltd.+NASDAQ%3A+QNTM%29+Receives+FDA+Clearance+to+Begin+Trials+for+Historic+MS+Treatment+/27039858.html Wed, 09 Sep 2026 08:30:00 -0400 QNTM http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Ltd.+NASDAQ%3A+QNTM%29+Receives+FDA+Clearance+to+Begin+Trials+for+Historic+MS+Treatment+/27039858.html <p>NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- via <a href="https://www.globenewswire.com/Tracker?data=f_kGscl0invYHTE5kFOCxxtqlOcxxqjY6ko6dLWavavpav2EHwFkCFosSVWa8iO-elLAV4M8UieMMju1OTFbew==" rel="nofollow" target="_blank">BioMedWire</a> — <a href="https://www.globenewswire.com/Tracker?data=MT9UzliMsHrm7UkS9ZbgpfYGxrbsvTw3GKWbf-9MHBxe2qVXvwc347wXbKGfYNB0jIBmsA_SjDebotktqkE2cSVJyOENApLZTMvu75PJ0y2usbEAg0pRWYLI7ngauyG907_gC_Z-oVUBcNd89daFKd8RfRyl7wCpKxKm_H5UUKE=" rel="nofollow" target="_blank">Quantum BioPharma Ltd.</a> (NASDAQ: QNTM) (CSE: QNTM) today announces its placement in an editorial published by <a href="https://www.globenewswire.com/Tracker?data=f_kGscl0invYHTE5kFOCx64-TlyfOtSoU6ovXpJoQ7TMLl12D0lSKR3TkaEnrLxp4Au9-ZzbGUaeBGaX4UnbCA==" rel="nofollow" target="_blank">BioMedWire</a> (BMW), one of 75+ brands within the <a href="https://www.globenewswire.com/Tracker?data=L703BjSxyNo-n6sy9QI_Z06tD6tMHAA09Oqi37ECXW1krKa_8Svd81U4GgPfQl68zR0ClzeCzonRzuSddvui-A7zk0DNC37e754amCGFZmbDOnCrcH_7UnpCSQI19ZCJg9lWCVIGmkzbrCbpvT4ETA==" rel="nofollow" target="_blank">Dynamic Brand Portfolio</a>@<a href="https://www.globenewswire.com/Tracker?data=H6Wvm6XbXEO_lElsiEHRPDNsp_8MtL6g5TO06CpfFuqAuui3kZhwo0EAf_aKIN_MN_B6qjBdUH5hyg3ag0oONQxSnNjH23BI4OKWYXg99Nw=" rel="nofollow" target="_blank">IBN</a> (<a href="https://www.globenewswire.com/Tracker?data=JAowqG4tafr-_LYyByHfekaQQ9OsqhYfdrdiFju7-UcEvzNMmAGgtTK2u4_3YkSc-7XlnW11-LxC1lxVYIsPYlxZWYJnQg1o0JK706QCkcI2QSpzEpuTgbbXai5R8QEF" rel="nofollow" target="_blank">InvestorBrandNetwork</a><u>)</u>, a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.</p> <p>To view the full publication, “A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach,” please visit: <a href="https://www.globenewswire.com/Tracker?data=TWkN9tWt81iJCypMQTVfTJ-MKBXjKs_P82afVWteLlwtzbzZ1U9pA4hP7-PN8nJTeHlQ5TtDjhpABwUEI_br7YSE2zSw4XpZGGITq15Ox38=" rel="nofollow" target="_blank">https://ibn.fm/b9zkB</a></p> http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Ltd.+NASDAQ%3A+QNTM%29+Receives+FDA+Clearance+to+Begin+Trials+for+Historic+MS+Treatment+/27039858.html Wed, 09 Sep 2026 08:30:00 -0400 QNTM http://www.streetinsider.com/Press+Releases/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html <p>AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=lQ1vfKp22ZB2ocbVfvEOXPytY4LFdfCKATaPKGH3O107ZhiAAlpXss-MniIhEDErt1hUQOYkS4barNHwZWYgXUqSPqxo5urNIyTW8qHKToQz0YEIsSztAJLMx4V-kJoKTswIqlxH09o02BqEw450CH_p80BPJI0SRkZR_JZA5IxzeWhWbMDmA2y6UZ260FVHHdgkSfx68kTNadW4zBTDquPlCi2WSCNOaHDw_VrsfWaKlObnPKoHwwANTkDkzi_6UMSVzVgYO0sjly9H5v3GrMETGrX9H5x_85NqQ6n6ndOqVGW1N_ZBiM69vdlqv2AZ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, <a href="https://www.globenewswire.com/Tracker?data=aR2tXahmjQt0upn-bRH3AI92ku8RsZllDZ_WCeOdBH8KE4sqZtfj2hFY6o7Q4n2b5nXG3u5Dur2UAZ83-2JVnw==" rel="nofollow" target="_blank">live</a> with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=INdZjwVMdTmJ9JZvlWHChXkwa7ooqKcX-Lfz6Z8jYcraE1Yvov2eAB1HnYGks3UZrZZrhYd35-PIQ5i65HHYcstLjaLN31709pylgSkXFr8L1mRfASlCUHpiJCY16FV4ako0uEg6fvWphkP7EUNVSg==" rel="nofollow" target="_blank">profile</a>) has http://www.streetinsider.com/Press+Releases/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html Tue, 08 Sep 2026 08:30:00 -0400 BIIB CLNN QNTM SNY http://www.streetinsider.com/Press+Releases/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html <p>AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=lQ1vfKp22ZB2ocbVfvEOXPytY4LFdfCKATaPKGH3O107ZhiAAlpXss-MniIhEDErt1hUQOYkS4barNHwZWYgXUqSPqxo5urNIyTW8qHKToQz0YEIsSztAJLMx4V-kJoKTswIqlxH09o02BqEw450CH_p80BPJI0SRkZR_JZA5IxzeWhWbMDmA2y6UZ260FVHHdgkSfx68kTNadW4zBTDquPlCi2WSCNOaHDw_VrsfWaKlObnPKoHwwANTkDkzi_6UMSVzVgYO0sjly9H5v3GrMETGrX9H5x_85NqQ6n6ndOqVGW1N_ZBiM69vdlqv2AZ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, <a href="https://www.globenewswire.com/Tracker?data=aR2tXahmjQt0upn-bRH3AI92ku8RsZllDZ_WCeOdBH8KE4sqZtfj2hFY6o7Q4n2b5nXG3u5Dur2UAZ83-2JVnw==" rel="nofollow" target="_blank">live</a> with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=INdZjwVMdTmJ9JZvlWHChXkwa7ooqKcX-Lfz6Z8jYcraE1Yvov2eAB1HnYGks3UZrZZrhYd35-PIQ5i65HHYcstLjaLN31709pylgSkXFr8L1mRfASlCUHpiJCY16FV4ako0uEg6fvWphkP7EUNVSg==" rel="nofollow" target="_blank">profile</a>) has http://www.streetinsider.com/Press+Releases/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html Tue, 08 Sep 2026 08:30:00 -0400 BIIB CLNN QNTM SNY http://www.streetinsider.com/Press+Releases/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html <p>AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=lQ1vfKp22ZB2ocbVfvEOXPytY4LFdfCKATaPKGH3O107ZhiAAlpXss-MniIhEDErt1hUQOYkS4barNHwZWYgXUqSPqxo5urNIyTW8qHKToQz0YEIsSztAJLMx4V-kJoKTswIqlxH09o02BqEw450CH_p80BPJI0SRkZR_JZA5IxzeWhWbMDmA2y6UZ260FVHHdgkSfx68kTNadW4zBTDquPlCi2WSCNOaHDw_VrsfWaKlObnPKoHwwANTkDkzi_6UMSVzVgYO0sjly9H5v3GrMETGrX9H5x_85NqQ6n6ndOqVGW1N_ZBiM69vdlqv2AZ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, <a href="https://www.globenewswire.com/Tracker?data=aR2tXahmjQt0upn-bRH3AI92ku8RsZllDZ_WCeOdBH8KE4sqZtfj2hFY6o7Q4n2b5nXG3u5Dur2UAZ83-2JVnw==" rel="nofollow" target="_blank">live</a> with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=INdZjwVMdTmJ9JZvlWHChXkwa7ooqKcX-Lfz6Z8jYcraE1Yvov2eAB1HnYGks3UZrZZrhYd35-PIQ5i65HHYcstLjaLN31709pylgSkXFr8L1mRfASlCUHpiJCY16FV4ako0uEg6fvWphkP7EUNVSg==" rel="nofollow" target="_blank">profile</a>) has http://www.streetinsider.com/Press+Releases/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html Tue, 08 Sep 2026 08:30:00 -0400 BIIB CLNN QNTM SNY http://www.streetinsider.com/Press+Releases/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html <p>AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=lQ1vfKp22ZB2ocbVfvEOXPytY4LFdfCKATaPKGH3O107ZhiAAlpXss-MniIhEDErt1hUQOYkS4barNHwZWYgXUqSPqxo5urNIyTW8qHKToQz0YEIsSztAJLMx4V-kJoKTswIqlxH09o02BqEw450CH_p80BPJI0SRkZR_JZA5IxzeWhWbMDmA2y6UZ260FVHHdgkSfx68kTNadW4zBTDquPlCi2WSCNOaHDw_VrsfWaKlObnPKoHwwANTkDkzi_6UMSVzVgYO0sjly9H5v3GrMETGrX9H5x_85NqQ6n6ndOqVGW1N_ZBiM69vdlqv2AZ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, <a href="https://www.globenewswire.com/Tracker?data=aR2tXahmjQt0upn-bRH3AI92ku8RsZllDZ_WCeOdBH8KE4sqZtfj2hFY6o7Q4n2b5nXG3u5Dur2UAZ83-2JVnw==" rel="nofollow" target="_blank">live</a> with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=INdZjwVMdTmJ9JZvlWHChXkwa7ooqKcX-Lfz6Z8jYcraE1Yvov2eAB1HnYGks3UZrZZrhYd35-PIQ5i65HHYcstLjaLN31709pylgSkXFr8L1mRfASlCUHpiJCY16FV4ako0uEg6fvWphkP7EUNVSg==" rel="nofollow" target="_blank">profile</a>) has http://www.streetinsider.com/Press+Releases/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html Tue, 08 Sep 2026 08:30:00 -0400 BIIB CLNN QNTM SNY http://www.streetinsider.com/Globe+Newswire/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html <p>AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=lQ1vfKp22ZB2ocbVfvEOXPytY4LFdfCKATaPKGH3O107ZhiAAlpXss-MniIhEDErt1hUQOYkS4barNHwZWYgXUqSPqxo5urNIyTW8qHKToQz0YEIsSztAJLMx4V-kJoKTswIqlxH09o02BqEw450CH_p80BPJI0SRkZR_JZA5IxzeWhWbMDmA2y6UZ260FVHHdgkSfx68kTNadW4zBTDquPlCi2WSCNOaHDw_VrsfWaKlObnPKoHwwANTkDkzi_6UMSVzVgYO0sjly9H5v3GrMETGrX9H5x_85NqQ6n6ndOqVGW1N_ZBiM69vdlqv2AZ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, <a href="https://www.globenewswire.com/Tracker?data=aR2tXahmjQt0upn-bRH3AI92ku8RsZllDZ_WCeOdBH8KE4sqZtfj2hFY6o7Q4n2b5nXG3u5Dur2UAZ83-2JVnw==" rel="nofollow" target="_blank">live</a> with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=INdZjwVMdTmJ9JZvlWHChXkwa7ooqKcX-Lfz6Z8jYcraE1Yvov2eAB1HnYGks3UZrZZrhYd35-PIQ5i65HHYcstLjaLN31709pylgSkXFr8L1mRfASlCUHpiJCY16FV4ako0uEg6fvWphkP7EUNVSg==" rel="nofollow" target="_blank">profile</a>) has http://www.streetinsider.com/Globe+Newswire/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html Tue, 08 Sep 2026 08:30:00 -0400 BIIB CLNN QNTM SNY http://www.streetinsider.com/Globe+Newswire/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html <p>AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=lQ1vfKp22ZB2ocbVfvEOXPytY4LFdfCKATaPKGH3O107ZhiAAlpXss-MniIhEDErt1hUQOYkS4barNHwZWYgXUqSPqxo5urNIyTW8qHKToQz0YEIsSztAJLMx4V-kJoKTswIqlxH09o02BqEw450CH_p80BPJI0SRkZR_JZA5IxzeWhWbMDmA2y6UZ260FVHHdgkSfx68kTNadW4zBTDquPlCi2WSCNOaHDw_VrsfWaKlObnPKoHwwANTkDkzi_6UMSVzVgYO0sjly9H5v3GrMETGrX9H5x_85NqQ6n6ndOqVGW1N_ZBiM69vdlqv2AZ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, <a href="https://www.globenewswire.com/Tracker?data=aR2tXahmjQt0upn-bRH3AI92ku8RsZllDZ_WCeOdBH8KE4sqZtfj2hFY6o7Q4n2b5nXG3u5Dur2UAZ83-2JVnw==" rel="nofollow" target="_blank">live</a> with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=INdZjwVMdTmJ9JZvlWHChXkwa7ooqKcX-Lfz6Z8jYcraE1Yvov2eAB1HnYGks3UZrZZrhYd35-PIQ5i65HHYcstLjaLN31709pylgSkXFr8L1mRfASlCUHpiJCY16FV4ako0uEg6fvWphkP7EUNVSg==" rel="nofollow" target="_blank">profile</a>) has http://www.streetinsider.com/Globe+Newswire/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html Tue, 08 Sep 2026 08:30:00 -0400 BIIB CLNN QNTM SNY http://www.streetinsider.com/Globe+Newswire/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html <p>AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=lQ1vfKp22ZB2ocbVfvEOXPytY4LFdfCKATaPKGH3O107ZhiAAlpXss-MniIhEDErt1hUQOYkS4barNHwZWYgXUqSPqxo5urNIyTW8qHKToQz0YEIsSztAJLMx4V-kJoKTswIqlxH09o02BqEw450CH_p80BPJI0SRkZR_JZA5IxzeWhWbMDmA2y6UZ260FVHHdgkSfx68kTNadW4zBTDquPlCi2WSCNOaHDw_VrsfWaKlObnPKoHwwANTkDkzi_6UMSVzVgYO0sjly9H5v3GrMETGrX9H5x_85NqQ6n6ndOqVGW1N_ZBiM69vdlqv2AZ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, <a href="https://www.globenewswire.com/Tracker?data=aR2tXahmjQt0upn-bRH3AI92ku8RsZllDZ_WCeOdBH8KE4sqZtfj2hFY6o7Q4n2b5nXG3u5Dur2UAZ83-2JVnw==" rel="nofollow" target="_blank">live</a> with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=INdZjwVMdTmJ9JZvlWHChXkwa7ooqKcX-Lfz6Z8jYcraE1Yvov2eAB1HnYGks3UZrZZrhYd35-PIQ5i65HHYcstLjaLN31709pylgSkXFr8L1mRfASlCUHpiJCY16FV4ako0uEg6fvWphkP7EUNVSg==" rel="nofollow" target="_blank">profile</a>) has http://www.streetinsider.com/Globe+Newswire/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html Tue, 08 Sep 2026 08:30:00 -0400 BIIB CLNN QNTM SNY http://www.streetinsider.com/Globe+Newswire/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html <p>AUSTIN, Texas, Sept. 08, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=lQ1vfKp22ZB2ocbVfvEOXPytY4LFdfCKATaPKGH3O107ZhiAAlpXss-MniIhEDErt1hUQOYkS4barNHwZWYgXUqSPqxo5urNIyTW8qHKToQz0YEIsSztAJLMx4V-kJoKTswIqlxH09o02BqEw450CH_p80BPJI0SRkZR_JZA5IxzeWhWbMDmA2y6UZ260FVHHdgkSfx68kTNadW4zBTDquPlCi2WSCNOaHDw_VrsfWaKlObnPKoHwwANTkDkzi_6UMSVzVgYO0sjly9H5v3GrMETGrX9H5x_85NqQ6n6ndOqVGW1N_ZBiM69vdlqv2AZ" rel="nofollow" target="_blank">BioMedWire Editorial Coverage</a>: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what they have already lost. Nearly one million people in the United States, and close to 2.9 million worldwide, <a href="https://www.globenewswire.com/Tracker?data=aR2tXahmjQt0upn-bRH3AI92ku8RsZllDZ_WCeOdBH8KE4sqZtfj2hFY6o7Q4n2b5nXG3u5Dur2UAZ83-2JVnw==" rel="nofollow" target="_blank">live</a> with that reality, watching a disease that can gradually erode mobility, vision, and basic bodily control. That gap has just gotten a serious new challenger. <strong>Quantum BioPharma Ltd.</strong> (NASDAQ: QNTM) (<a href="https://www.globenewswire.com/Tracker?data=INdZjwVMdTmJ9JZvlWHChXkwa7ooqKcX-Lfz6Z8jYcraE1Yvov2eAB1HnYGks3UZrZZrhYd35-PIQ5i65HHYcstLjaLN31709pylgSkXFr8L1mRfASlCUHpiJCY16FV4ako0uEg6fvWphkP7EUNVSg==" rel="nofollow" target="_blank">profile</a>) has http://www.streetinsider.com/Globe+Newswire/A+Micro-Cap+Biotech+Just+Cleared+a+Milestone+Most+Never+Reach/27033758.html Tue, 08 Sep 2026 08:30:00 -0400 BIIB CLNN QNTM SNY http://www.streetinsider.com/New+Coverage/Rodman+%26+Renshaw+Starts++%28QNTM%29+at+Buy/27000943.html <p>Rodman & Renshaw analyst Michael King Jr. initiates coverage on (NASDAQ: QNTM) with a Buy rating and a price target of $8.00.</p><p>The analyst comments "We are initiating coverage of Quantum BioPharma with a BUY rating and $8 price target based on LUCID-MS, a potentially first-in-class non-immunomodulatory small molecule positioned to address neurodegeneration and disability progression in progressive multiple sclerosis, where therapeutic options remain limited."</p><p>For an analyst ratings summary and ratings history on <a href="http://www.streetinsider.com/rating_history.php?q=QNTM">click here</a>. For more ratings news on <a href="http://www.streetinsider.com/stock_lookup_news.php?q=QNTM&amp;type=analyst">click here</a>.</p><p>Shares of closed at $3.08 yesterday.</p> http://www.streetinsider.com/New+Coverage/Rodman+%26+Renshaw+Starts++%28QNTM%29+at+Buy/27000943.html Mon, 31 Aug 2026 07:03:22 -0400 QNTM http://www.streetinsider.com/Analyst+Comments/Rodman+%26+Renshaw+Starts++%28QNTM%29+at+Buy/27000943.html <p>Rodman & Renshaw analyst Michael King Jr. initiates coverage on (NASDAQ: QNTM) with a Buy rating and a price target of $8.00.</p><p>The analyst comments "We are initiating coverage of Quantum BioPharma with a BUY rating and $8 price target based on LUCID-MS, a potentially first-in-class non-immunomodulatory small molecule positioned to address neurodegeneration and disability progression in progressive multiple sclerosis, where therapeutic options remain limited."</p><p>For an analyst ratings summary and ratings history on <a href="http://www.streetinsider.com/rating_history.php?q=QNTM">click here</a>. For more ratings news on <a href="http://www.streetinsider.com/stock_lookup_news.php?q=QNTM&amp;type=analyst">click here</a>.</p><p>Shares of closed at $3.08 yesterday.</p> http://www.streetinsider.com/Analyst+Comments/Rodman+%26+Renshaw+Starts++%28QNTM%29+at+Buy/27000943.html Mon, 31 Aug 2026 07:03:22 -0400 QNTM http://www.streetinsider.com/FDA/Quantum+BioPharma+gets+FDA+nod+for+Lucid-MS+Phase+2+MS+trial/26924410.html <p>Quantum BioPharma Ltd. (NASDAQ: QNTM) reported its second quarter 2026 financial results, disclosing that the U.S. Food and Drug Administration approved its Investigational New Drug application for Lucid-MS on Aug. 10, 2026, clearing the company to proceed with a randomized, double-blind, placebo-controlled Phase 2 clinical trial in patients with progressive multiple sclerosis.</p> <p>As of June 30, 2026, the company held combined cash, cash equivalents, and digital assets of approximately $9.5 million, up from $4.1 million at December 31, 2025. Cash and cash equivalents rose to $3.65 million from $1.91 million over the same period. Management stated that current liquidity is sufficient http://www.streetinsider.com/FDA/Quantum+BioPharma+gets+FDA+nod+for+Lucid-MS+Phase+2+MS+trial/26924410.html Fri, 14 Aug 2026 07:00:16 -0400 QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Strengthens+Equity+and+Liquidity+in+Q2+2026+as+FDA+Approves+Lucid-MS+for+Pivotal+Phase+2+Clinical+Trial/26924378.html <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its financial and operational results for the second quarter of 2026, ended June 30, 2026.</p> <p align="justify">As of June 30, 2026, the Company’s combined cash and cash equivalents, and digital assets, totaled approximately US$9.5 million, an increase from US$4.1 million as of December 31, 2025. Assuming the current cash burn rate for the first half of 2026, management confirms that current liquidity is sufficient to fund planned operations to at least October 2027.</p> http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Strengthens+Equity+and+Liquidity+in+Q2+2026+as+FDA+Approves+Lucid-MS+for+Pivotal+Phase+2+Clinical+Trial/26924378.html Fri, 14 Aug 2026 07:00:00 -0400 QNTM http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Strengthens+Equity+and+Liquidity+in+Q2+2026+as+FDA+Approves+Lucid-MS+for+Pivotal+Phase+2+Clinical+Trial/26924378.html <p align="justify">TORONTO, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum" or the "Company"), has reported its financial and operational results for the second quarter of 2026, ended June 30, 2026.</p> <p align="justify">As of June 30, 2026, the Company’s combined cash and cash equivalents, and digital assets, totaled approximately US$9.5 million, an increase from US$4.1 million as of December 31, 2025. Assuming the current cash burn rate for the first half of 2026, management confirms that current liquidity is sufficient to fund planned operations to at least October 2027.</p> http://www.streetinsider.com/Globe+Newswire/Quantum+BioPharma+Strengthens+Equity+and+Liquidity+in+Q2+2026+as+FDA+Approves+Lucid-MS+for+Pivotal+Phase+2+Clinical+Trial/26924378.html Fri, 14 Aug 2026 07:00:00 -0400 QNTM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Quantum+Biopharma+Ltd.++++For%3A+Aug+14/26924418.html si-local-file:///var/storage/secattach/20260814/26924418.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Quantum+Biopharma+Ltd.++++For%3A+Aug+14/26924418.html Fri, 14 Aug 2026 07:00:00 -0400 O.39443675 QNTM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Quantum+Biopharma+Ltd.++++For%3A+Aug+14/26924418.html si-local-file:///var/storage/secattach/20260814/26924418.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Quantum+Biopharma+Ltd.++++For%3A+Aug+14/26924418.html Fri, 14 Aug 2026 07:00:00 -0400 O.39443675 QNTM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Quantum+Biopharma+Ltd.++++For%3A+Jun+30/26920911.html si-local-file:///var/storage/secattach/20260813/26920911.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Quantum+Biopharma+Ltd.++++For%3A+Jun+30/26920911.html Thu, 13 Aug 2026 16:08:00 -0400 O.39443675 QNTM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Quantum+Biopharma+Ltd.++++For%3A+Jun+30/26920911.html si-local-file:///var/storage/secattach/20260813/26920911.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Quantum+Biopharma+Ltd.++++For%3A+Jun+30/26920911.html Thu, 13 Aug 2026 16:08:00 -0400 O.39443675 QNTM http://www.streetinsider.com/SEC+Filings/Form++6-KA++++++Quantum+Biopharma+Ltd.++++For%3A+Aug+13/26918485.html si-local-file:///var/storage/secattach/20260813/26918485.html http://www.streetinsider.com/SEC+Filings/Form++6-KA++++++Quantum+Biopharma+Ltd.++++For%3A+Aug+13/26918485.html Thu, 13 Aug 2026 11:07:00 -0400 O.39443675 QNTM http://www.streetinsider.com/SEC+Filings/Form++6-KA++++++Quantum+Biopharma+Ltd.++++For%3A+Aug+13/26918485.html si-local-file:///var/storage/secattach/20260813/26918485.html http://www.streetinsider.com/SEC+Filings/Form++6-KA++++++Quantum+Biopharma+Ltd.++++For%3A+Aug+13/26918485.html Thu, 13 Aug 2026 11:07:00 -0400 O.39443675 QNTM http://www.streetinsider.com/FDA/Quantum+BioPharma+gets+FDA+clearance+for+Lucid-MS+phase+2+MS+trial/26894040.html <p>Quantum BioPharma Ltd. (NASDAQ: QNTM, CSE: QNTM) announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug application for Lucid-MS (Lucid-21-302), allowing the company to proceed with a Phase 2 clinical trial in patients with progressive multiple sclerosis.</p> <p>The planned trial will be a randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of Lucid-MS in people with progressive MS, including primary progressive MS and secondary progressive MS. Trial start-up activities, including site selection, are already underway, according to a company statement.</p> <p>Lucid-MS is described as a patented new chemical entity designed to inhibit demyelination by http://www.streetinsider.com/FDA/Quantum+BioPharma+gets+FDA+clearance+for+Lucid-MS+phase+2+MS+trial/26894040.html Mon, 10 Aug 2026 07:00:15 -0400 QNTM http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Receives+United+States+FDA+Clearance+To+Proceed+with+Lucid-MS+Phase+2+Trial+in+Progressive+Multiple+Sclerosis%3A/26894004.html <p align="center"><em>Major Regulatory Milestone Positions Company to Initiate Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Patented First-in-Class Neuroprotective Therapy Targeting Demyelination </em></p> <p align="center"><em>Lucid-MS Advances Novel Disease-Modifying Approach Targeting Multi-Billion Dollar Progressive MS Market with Significant Unmet Medical Need Worldwide</em></p> <p align="justify">TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“<strong>Quantum BioPharma</strong>”), a transformative biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurological, metabolic, and alcohol misuse disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational http://www.streetinsider.com/Press+Releases/Quantum+BioPharma+Receives+United+States+FDA+Clearance+To+Proceed+with+Lucid-MS+Phase+2+Trial+in+Progressive+Multiple+Sclerosis%3A/26894004.html Mon, 10 Aug 2026 07:00:00 -0400 QNTM